Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · May 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a type of radiation treatment called hypofractionated radiotherapy, which is given to women with early breast cancer or a specific type of non-invasive breast cancer known as ductal carcinoma in situ (DCIS). The goal is to see if giving a higher dose of radiation directly to the area where the tumor was removed (the tumor bed) can help treat the cancer more effectively after a surgery called breast-conserving surgery, where only part of the breast is removed.

To qualify for this trial, participants need to be women aged 20 and older with certain early-stage breast cancer conditions. They should also be in good overall health and have a good chance of living at least five more years. During the trial, participants will receive the new radiation treatment and will be monitored closely for any side effects or benefits. This study is currently recruiting participants, so if you or someone you know might be interested, it could be a good opportunity to contribute to breast cancer research while receiving potentially beneficial treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS).
• • Patients undergoing breast-conserving surgery
• • Age ≥ 20 years
• • Karnofsky Performance Status (KPS) ≥70%
• • Life expectancy ≥ 5 years
• • Adequate renal and hepatic function
• Exclusion Criteria:
• • Pregnant patients
• • Patients requiring re-irradiation of the thoracic region